FDA Grants AMDL Clearance to Market the AMDL-ELISA DR-70(R) (FDP) Blood Test for Monitoring Colorec...(nts and are subject to numerous risks an...),Health
FDA Grants AMDL Clearance to Market the AMDL-ELISA DR-70(R) (FDP) Blood Test for Monitoring Colorectal Cancer
nts and are subject to numerous risks and uncertainties includingthe... AMDL Contact: Kristine Szarkowitz ... 206.310.5323 ... 206.201.3286 ... kszarkowitz@amdl...
nts and are subject to numerous risks and uncertainties, including
the market's acceptance or demand for DR-70 or any of the Company's
products, failure to complete successfully the development of other new or
enhanced products, the Company's future capital needs, any actions by the
Company's distribution channels that may be adverse to the Company, the
success of competitive products, other economic factors affecting the
Company and its markets, and other risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission. The actual
results may differ materially from those contained in this press release.
The Company disclaims any obligation to update any statements in this press
release.